BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1632-1643. [PMID: 32520312 DOI: 10.1093/ecco-jcc/jjaa120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Gonzalez HA, Myers S, Whitehead E, Pattinson A, Stamp K, Turnbull J, Fory R, Featherstone B, Wilkinson A, Lisle J, Haire G, Henderson E, Sebastia S. React, reset and restore: Adaptation of a large inflammatory bowel disease service during COVID-19 pandemic. Clin Med (Lond) 2020;20:e183-8. [PMID: 32719036 DOI: 10.7861/clinmed.2020-0369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep 2021;48:5745-58. [PMID: 34296352 DOI: 10.1007/s11033-021-06565-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Zhang C, Qi W, Li Y, Tang M, Yang T, Liu K, Chen Y, Deng D, Xiang M, Chen L. Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem 2021;64:1966-88. [PMID: 33593051 DOI: 10.1021/acs.jmedchem.0c01468] [Reference Citation Analysis]
5 Papa A, Papa V, Lopetuso LR, Gasbarrini A, Tursi A. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therap Adv Gastroenterol 2020;13:1756284820968747. [PMID: 33149764 DOI: 10.1177/1756284820968747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Barnes A, Andrews J, Spizzo P, Mountifield R. Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic. JGH Open 2021;5:585-9. [PMID: 34013059 DOI: 10.1002/jgh3.12537] [Reference Citation Analysis]
7 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Barberio B, Zingone F, Bertani L, Savarino E. The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? Gastroenterology 2021;160:1903-4. [PMID: 32687929 DOI: 10.1053/j.gastro.2020.07.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]